Effect of the HSF1 inhibitor Cl-43 on tumors and non-transformed cells
- Authors: Vladimirova S.A.1, Margulis B.A.1, Guzhova I.V.1, Nikotina A.D.1
-
Affiliations:
- Institute of Cytology, Russian Academy of Sciences
- Issue: Vol 66, No 2 (2024)
- Pages: 143-149
- Section: Articles
- URL: https://journals.rcsi.science/0041-3771/article/view/262328
- DOI: https://doi.org/10.31857/S0041377124020049
- EDN: https://elibrary.ru/RKHDEK
- ID: 262328
Cite item
Abstract
The occurrence of severe side effects in patients undergoing chemotherapy remains a significant clinical challenge. Therefore, the urgent task is to search for tumor-specific therapies that target opposing responses in non-transformed and tumorigenic cells. HSF1 is known to be an important marker of cancer progression and its transcriptional activity products allow tumor cells to escape the adverse effects of anticancer therapies. Thus, drugs inhibiting HSF1 activity hold promise as a therapeutic strategy. Our study shows that using the cardenolide group’s HSF1 activity inhibitor, CL-43, provides cytoprotective effects on primary, untransformed dermal fibroblast (DF-2) cells, making them less sensitive to etoposide, whereas we observed an increase in sensitivity in the DLD1 tumor cell line. Furthermore, our results show that CL-43 interferes with the intranuclear transport of the active form of HSF1, increasing its activity and consequently the synthesis of HSP70 in human fibroblasts, while suppressing this activity in tumor cells in a dose-dependent manner. Our findings demonstrate the unique potential of CL-43 as a tumor-specific compound with high therapeutic value.
Keywords
Full Text
About the authors
S. A. Vladimirova
Institute of Cytology, Russian Academy of Sciences
Email: nikotina.ad@gmail.com
Russian Federation, St. Petersburg, 194064
B. A. Margulis
Institute of Cytology, Russian Academy of Sciences
Email: nikotina.ad@gmail.com
Russian Federation, St. Petersburg, 194064
I. V. Guzhova
Institute of Cytology, Russian Academy of Sciences
Email: nikotina.ad@gmail.com
Russian Federation, St. Petersburg, 194064
A. D. Nikotina
Institute of Cytology, Russian Academy of Sciences
Author for correspondence.
Email: nikotina.ad@gmail.com
Russian Federation, St. Petersburg, 194064
References
- Ajmeera D., Ajumeera R. 2023. Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance. Genes Dis. V. 11. P. 148. https://doi.org/10.1016/j.gendis.2022.12.013
- Banerjee M., Cui X., Li Z., Yu H., Cai L., Jia X., Daheng H., Wang C., Gao T., Xie Z. 2018. Na/K-ATPase Y260 phosphorylation-mediated Src regulation in control of aerobic glycolysis and tumor growth. Sci. Rep. V. 8. P. 1. http://dx.doi.org/10.1038/s41598-018-29995-2
- Botelho A.F.M., Pierezan F., Soto-Blanco B., Melo M.M. 2019. A review of cardiac glycosides: structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential. Toxicon. V. 158. P. 63. https://doi.org/10.1016/j.toxicon.2018.11.429
- Carpenter R.L., Paw I., Dewhirst M.W. and Lo H-W. 2015. Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial- mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Oncogene. V. 34. P. 546.
- Carpenter R.L., Yesim G-P. 2019. HSF1 as a cancer biomarker and therapeutic target. Curr. Cancer Drug Targets. V. 19. P. 515.
- Cerella C., Dicato M., Diederich M. 2013. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion. V. 13. P. 225. http://dx.doi.org/10.1016/j.mito.2012.06.003
- Dai C., Sampson S.B. 2016. HSF1: guardian of proteostasis in cancer Chengkai. Trends Cell Biol. V. 26. P. 17.
- Dai C. 2018. The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis. Philos. Trans. R. Soc. B. Biol. Sci. V. 373. P. 20160525.
- Gao Q.X., Zhou G.X., Lin S.J., Paus R., Yue Z.C. 2019. How chemotherapy and radiotherapy damage the tissue: comparative biology lessons from feather and hair models. Exper. Dermatol. V. 28. P. 413.
- Guo Y., Guettouche T., Fenna M., Boellmann F., Pratt W.B., Toft D.O., Smith D.F., Voellmy R. 2001. Evidence for a mechanism of repression of Heat Shock Factor 1 transcriptional activity by a multichaperone complex. J. Biol. Chem. V. 276. P. 45791. http://dx.doi.org/10.1074/jbc.M105931200
- Irby R.B., Yeatman T.J. 2000. Role of Src expression and activation in human cancer. Oncogene. V. 19. P. 5636. http://dx.doi.org/10.1038/sj.onc.1203912
- Kim N., Yim H.Y., He N., Lee C.J., Kim J.H., Choi J.S., Lee H.S., Kim S., Jeong E., Song M., Jeon S-M., Kim W-Y., Mills G.B., Cho Y-Y., Yoon S. 2016. Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Sci. Rep. V. 6. P. 29721.
- Neef D.W., Jaeger A., Gomez-Pastor R., Willmund F., Frydman J., Thiele D.J. 2014. A direct regulatory interaction between chaperonin TRiC and stress responsive transcription factor HSF1. Cell Rep. V. 9. P. 955.
- Neudegger T., Verghese J., Hayer-Hartl M., Hartl F.U., Bracher A. 2016. Structure of human heat-shock transcription factor 1 in complex with DNA. Nat. Struct. Mol. Biol. V. 23. P. 140.
- Nikotina A.D., Koludarova L., Komarova E.Y., Mikhaylova E.R., Aksenov N.D., Suezov R., Kartzev V.G., Margulis B.A., Guzhova I.V. 2018. Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells. Oncotarget. V. 9. P. 27268.
- Shen J., Zhan Y., Li H., Wang Z. 2020. Ouabain impairs cancer metabolism and activates AMPK-Src signaling pathway in human cancer cell lines. Acta Pharmacol. Sin. V. 41. P. 110. http://dx.doi.org/10.1038/s41401-019-0290-0
- Wang Y., Zhan Y., Xu R., Shao R., Jiang J., Wang Z. 2015. Src mediates extracellular signal-regulated kinase 1/2 activation and autophagic cell death induced by cardiac glycosides in human non-small cell lung cancer cell lines. Mol. Carcinog. V. 54. P. 26.